Ann Thorac Surg 1996;62:433-434
© 1996 The Society of Thoracic Surgeons
Discussion
Discussion
| The first 20% of the full text of this article appears below. |
See also page 425.
DR CARMELO A. MILANO (Durham, NC): I compliment Dr Magovern and associates on an excellent report, which I had the opportunity to review before this session. This is very novel work, particularly the use of vascular endothelial growth factor, and the potential clinical applications are obvious. We at Duke University Medical Center also have made efforts to transfer genes to the myocardium using an adenovirus vector.
We began, as you did, using a recombinant adenovirus, which was directly injected into the myocardium. We have achieved strong ß-galactosidase expression after direct injection, as you have shown with a different reporter gene.
Our goal in undertaking these studies was to overexpress myocardial ß-adrenergic receptor genes for the purpose of enhancing ventricular function. We have used several different species with direct injection of recombinant, replication-deficient adenovirus containing the ß-adrenergic receptor. Very marked overexpression of the ß-adrenergic receptor can be obtained several days after direct injection of the adenovirus. We are concerned, however, about substantial inflammation and fibrosis, which developed at the site of the injection. We subsequently tried intracoronary administration of the adenovirus (both with reporter genes and with a ß-adrenergic receptor gene) and have been able to achieve good levels of expression. Surprisingly, we have found less inflammatory response with intracoronary . . . [Full Text of this Article]
Related Article
-
Direct In Vivo Gene Transfer to Canine Myocardium Using a Replication-Deficient Adenovirus Vector
- Christopher J. Magovern, Charles A. Mack, John Zhang, Rebecca T. Hahn, Wilson Ko, O. Wayne Isom, Ronald G. Crystal, and Todd K. Rosengart
Ann. Thorac. Surg. 1996 62: 425-433.
[Abstract]
[Full Text]
Copyright © 1996 by The Society of Thoracic Surgeons.
